It’s safe to stretch the interval between adalimumab doses

Patients with rheumatoid arthritis (RA) with high serum levels of adalimumab can safely reduce potential over-exposure to the drug by prolonging the interval between doses, a study shows.

Researchers in the Netherlands found that patients on adalimumab with serum drug levels above 8µg/mL can be reduced to three-weekly dosing with no reduction in efficacy.

The open label, non-inferiority trial compared 27 patients taking the normal fortnightly 40mg dose with the same number taking it every three weeks.

They found no difference in disease activity between the